Abstract
Half a decade ago, a provocative editorial envisioned a “rematch” between globus pallidus pars interna (GPi) and subthalamic nucleus (STN) deep brain stimulation (DBS) in the treatment of advanced Parkinson disease (PD).1 The idea of a boxing bout between the 2 most common DBS targets for the treatment of PD summarized a decade-long controversy. While GPi had been the preferred target of ablative procedures for the treatment of advanced PD in the 1990s, the advent of DBS coincided with an overwhelming preference for the STN. Such instantaneous supremacy was originally supported by a theoretical rationale, namely the central role of the STN in the pathophysiology of PD,2 but for over a decade it remained fundamentally based on preference more than evidence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
